Front Line Covid Specialists: "NIH- Please Read our Data!"
On Dec 8, 2020, committee chairman Republican Sen. Ron Johnson called ICU Pulmonary specialist Dr. Pierre Kory of the Aurora St. Luke’s Medical Center (WI) and president of the FLCCC to the US Senate Homeland Security and Governmental Affairs Committee. The hearing was called “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II.” Dr. Kory gave his testimony on behalf of frontline physicians about the current state of care in the Covid pandemic and what his group specifies as the logic-based treatment with scientifically proven data that he pleads the NIH to review. (See complete video and Transcript of Dr. Kory's Testimony)
According to health officials at the FLCCC (Front Line Covid-19 Care Alliance), a new report of a prophylactic solution & a treatment protocol for Covid-19 infection is available in the global market NOW. This community of intensivists in FLCCC expresses tremendous confidence in this clinical strategy with climbing evidence of success domestically and abroad., "... in keeping with the robust and emerging evidence reviewed above, the Front Line COVID-19 Critical Care Alliance recently created a prophylaxis and early treatment approach for COVID-19 called “I-MASK+”. This protocol includes IVERMECTIN as a core therapy in both early treatment and prophylaxis of both high-risk patients and post-exposure to household members with COVID-19 . The Front Line COVID-19 Critical Care Alliance is committed to measuring outcomes in those treated with ivermectin and reviewing all emerging results from the current and any future clinical trials of Ivermectin in COVID19"
NOT JUST FOR SCABIES... IVERMECTIN FOR COVID-19 SHOWS SUCCESS FROM ICU DOCS If you looked up IVERMECTIN in 2019 or earlier (pre-pandemic), you may find it as a topical anti-bacterial to popularly treat SCABIES (and kill scabies mites). It is also known as an oral antiparasitic agent approved for the treatment of worm infestations. Evidence suggests that oral ivermectin may be a safe and effective treatment for scabies; however, ivermectin is not FDA-approved for this use. [4-cdc]. Scabies is an infestation of the skin by the human itch mite (Sarcoptes scabiei var. hominis). The microscopic scabies mite burrows into the upper layer of the skin where it lives and lays its eggs. Scabies is found worldwide and affects people of all races and social classes. Scabies can spread rapidly under crowded conditions where close body and skin contact is frequent. Institutions such as nursing homes, extended-care facilities, and prisons are often sites of scabies outbreaks. Child-care facilities also are a common site of scabies infestations. [5-cdc] In addition, Ivermectin is FDA-approved for use in animals for prevention of heartworm disease in some small animal species, and for treatment of certain internal and external parasites in various animal species. People should never take animal drugs, as the FDA has only evaluated their safety and effectiveness in the particular species for which they are labeled. Using these products in humans could cause serious harm. [6-fda] Today, a unified global voice in the medical community for alternative care of Covid-19 infection is offering new scientific data supporting the surprising benefits of Ivermectin. The FLCCC (Front Line COVID-19 Critical Care Alliance) reported over 30 countries from Europe, the Americas, Asia and Africa now have growing communities of subscribers to this protocol, employing and attesting to the positive response that Ivermectin appears to provide in the prevention or care of Covid patients. According to Dr. Paul Marik of Eastern Virginia Medical School, "There is no one silver bullet... there are a few things that we should be doing simultaneously to control the virus. There is now overwhelming evidence is profoundly efficient in treating this disease- in preventing it early and in the late phase... what makes Ivermectin truly a remarkable drug is that not only is it a potent antibacterial and an anti-viral drug (but) it is a potent anti-inflammatory drug. So it's all the 'magic' you want in one pull" (see Dr. Marik's complete video interview) Also: see Prophylaxis & Early Outpatient Treatment Protocol for Covid-19 (source: FLCCC) Contributor: ROBERT L. BARD, MD, PC, DABR, FASLMSRecipient of nationally acclaimed Ellis Island Award (2020) for his lifetime achievement in advanced cancer diagnostic imaging. He co-founded the 9/11 CancerScan program to bring additional diagnostic support to all first responders from Ground Zero. His main practice in midtown, NYC (Bard Diagnostic Imaging- www.CancerScan.com) uses the latest in digital imaging technology and has been also used to help guide biopsies and in many cases, even replicate much of the same reports of a clinical invasive biopsy. Imaging solutions such as high-powered sonograms, Power Doppler Histogram, sonofluoroscopy, 3D/4D image reconstruction and the Power Doppler Histogram are safe, noninvasive, and do not use ionizing radiation. |
The following overview is a repost of the current feature published by the FLCCC Alliance and Dr. Pierre Kory.
Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19
source: www.covid19criticalcare.com |
One year into the pandemic, the only therapy considered “proven” as an effective treatment in COVID-19 is the use of corticosteroids in patients with moderate to severe illness.18 Similarly most concerning is the fact that little has proven effective to prevent disease progression to prevent hospitalization.
Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and antiinflammatory properties in laboratory studies. In the past 4 months, numerous, controlled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin.
Despite this growing list of failed therapeutics in COVID-19, it now appears that ivermectin, a widely used anti-parasitic medicine with known anti-viral and anti-inflammatory properties is proving a highly potent and multi-phase effective treatment against COVID-19. Although much of the trials data supporting this conclusion is available on medical pre-print servers or posted on clinicaltrials.gov, most have not yet undergone peer-review. Despite this limitation, the FLCCC expert panel, in their prolonged and continued commitment to reviewing the emerging medical evidence base, and considering the impact of the recent surge, has now reached a consensus in recommending that ivermectin for both prophylaxis and treatment of COVID-19 should be systematically and globally adopted.
The FLCCC recommendation is based on the following set of conclusions derived from the existing data, which will be comprehensively reviewed below:
1) Since 2012, multiple in-vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue and others
2) Ivermectin inhibits SARS-CoV-2 replication, leading to absence of nearly all viral material by 48h in infected cell cultures
3) Ivermectin has potent anti-inflammatory properties with in-vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-κB (NF-κB), the most potent mediator of inflammation
4) Ivermectin significantly diminishes viral load and protects against organ damage when administered to mice upon infection with a virus similar to SARS-CoV-232
5) Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients
6) Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms
8) Ivermectin reduces mortality in critically ill patients with COVID-19
9) Ivermectin leads to striking reductions in case-fatality rates in regions with widespread use
10) The safety, availability, and cost of ivermectin is nearly unparalleled given its near nil drug interactions along with only mild and rare side effects observed in almost 40 years of use and billions of doses administered
11) The World Health Organization has long included ivermectin on its “List of Essential Medicines”
Exposure prophylaxis studies of Ivermectin’s ability to prevent transmission of COVID-19
Data is also now available showing large and statistically significant decreases in the transmission of COVID-19 among human subjects based on data from three randomized controlled trials (RCT) and one retrospective observational study (OCT); however, none of the studies have been peer-reviewed yet.
The largest RCT was posted on the Research Square pre-print server on November 13, 2020 while the two other RCT’s have submitted data to clinicaltrials.gov, which then performed a quality control review and posted the results. The OCT was posted on the pre-print server medRxiv on November 3, 2020.The largest RCT by Elgazzar and colleagues at Benha University in Egypt randomized 200 health care and households contacts of COVID-19 patients where 100 patients took a high dose of 0.4mg/kg on day 1 and repeated the dose on day 7 in addition to wearing personal protective equipment (PPE), while the control group of 100 contacts wore PPE only.52 There was a large and statistically significant reduction in contacts tesing positive by RT-PCR when treated with ivermectin vs. controls, 2% vs 10%, p<.05.
The second largest RCT, conducted in Egypt by Shouman et al. at Zagazig University, included 340 (228 treated, 112 control) family members of patients positive for SARS-CoV-2 via PCR.
Based on both their study finding and the Egyptian prophylaxis study, the All India Institute of Medical Sciences included a consensus statement in the manuscript recommending health care workers take two 0.3mg/kg doses of ivermectin 72 hours apart and to repeat monthly.
For the complete report, visit: www.covid19criticalcare.com
VIEWPOINTS
"Dr. Kory's testimony to a Congressional Hearing on the benefits of a 40 year history in clinical medicine of a simple and inexpensive drug repurposed for the treatment of his current Covid 19 patients could not be more important in these times. The clinical experience and research of a physician who cares passionately about his patients, as well as the current state of worldwide treatment for Covid victims, is critical in overcoming our problems. He is an inspiration to all physicians and patients alike. It is common practice for us to utilize available drugs in "off label" application where our patient's health is our responsibility and clinical experience as well as the literature supporting our prescription. What he is recommending has been done continually for years and years by physicians who care for patients. He uses ivermectin because it helps his patients. We need to use ivermectin in the manner recommended as well as any other effective protocol shown to be helpful in patient care for our patients."
ROBERTA KLINE, MD - Obstetrics/Gynecology & Genomic Education | Santa Fe, NM
"This is an amazing SUCCESS story of using science to guide a collaborative effort to solve clinical challenges quickly. From my perspective of supporting each person's biochemistry for health, I'm glad to see they included antioxidant and vitamin support to enhance efficacy. But this story is also one that highlights the frustration around politics, money and power controlling low-cost, innovative solutions that are more effective than pricey designer drugs. This information needs to get out. NOW. We may now have a vaccine that can help in the long term, but people are getting sick and dying in record numbers. My neighbor is a nurse administrator at our local hospital here, where COVID is finally overwhelming them and they have shut down elective surgeries for the first time in the pandemic. I have reached out to her to share this information and hope approval can be expedited so this can make a difference."
"I am a cardiac anesthesiologist and intensivist which allows me to work on a different level with critical patients. I am the only member of FLCCC from former Soviet Union countries and am the only one in my country who uses this (MATH+) protocol. I am very proud that I started using this protocol in many patients and I can see faster recovery from Covid-19. Unfortunately, we do not have Ivermectin in our country but I would like to say that the MATH+ protocol works very well even without Ivermectin. My whole work is based in world standards. This war urged us to work differently... in order to get good results."
NOELLE L. CUTTER, Ph.D - Molloy College | Assoc. Professor of Biology & Chemistry | NY
"The incredible work that has emerged from the group of scholars working on the MATH+ formula for patient care reminds me of the importance of collaboration in medicine. This treatment formula was designed with patient care in mind, during an unprecedented time in our history. The formula has clearly been shown to be an effective treatment to combat the virus. The combination of Corticosteroids, Ascorbic acid and Heperin has effectively been shown to reduce severity of patient symptoms and greatly reduce the need for the ventilator. This is certainly a step forward in treatment options for COVID19 patients." - ELIZABETH BANCHITTA - EMT / Medical Student - NY
"I feel Dr. Kory's testimonial - it comes from the deep end of the ICU where most of the patients are extremely critical and there's not that many interventions that would make much of a difference. I can't imagine being so highly trained and knowing exactly how something works and thinking, 'I know this will work but I can't give it to my patients and they're going to die possibly for no reason'. Meanwhile, we don't know how the vaccine is going to play out, but regardless of that, there needs to be other resources."
FROM THE NIH COVID-19 TREATMENT GUIDELINES: IVERMECTIN Last Updated: August 27, 2020 "Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug that is used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.1 It is also being evaluated for its potential to reduce the rate of malaria transmission by killing mosquitoes that feed on treated humans and livestock.2 For these indications, ivermectin has been widely used and has demonstrated an excellent safety profile. Recommendation: The COVID-19 Treatment Guidelines Panel recommends against the use of ivermectin for the treatment of COVID-19, except in a clinical trial (AIII). The available clinical data on the use of ivermectin to treat COVID-19 are limited." See complete NIH report and references: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ivermectin/
|
Teams of American physicians like Dr. Pierre Kory, Pulmonary and Critical Care Specialist (Milwaukee, WI) and his team of front-line Covid care providers (the Front Line Covid-19 Critical Care Alliance) challenged Dexamethasone as the exalted panacea of the pandemic. Dr. Kory’s team dedicated their life’s work to the research and treatment of infectious diseases in critical illness, and recently published a battle-tested and proven Hospital Treatment Protocol called MATH+, a combination of medicines designed to counteract the injurious hyperinflammation, hypercoagulability, and hypoxemia in COVID-19 using synergistic actions. Their group strongly recommends a different corticosteroid called METHYLPREDNISOLONE. Work done by members of the group, in particular, Dr. G. Umberto Meduri, one of the worlds experts on the use of corticosteroids in critical illness, discovered key findings establishing the rationale in support of the preferred use of Methylprednisolone, while also providing a wider scope of evidence supporting corticosteroid therapy for Covid-19 critical cases.
ON PREVENTION: Survival Guide from ICU Docs + THE FOUR D'S of Airborne Transmission
"Arguably, most doctors are not like INTENSIVISTS (ICU specialists)... they are the last line with the dying and (those with) the most severe illnesses. They are conditioned to work creatively and more aggressively under a major time limit... to reverse life threatening disorders." Read about how front line ICU docs maintain their health through the Covid pandemic. Review their latest safety protocols in INFECTION CONTROLS of routine mask wearing, regular hand-washing and gown donning. Get additional insight on supplements and a comprehensive review of how to truly manage airborne pathogens. (see complete article)
Disclaimer & Copyright Notice: The materials provided on this website are copyrighted and the intellectual property of the publishers/producers (The NY Cancer Resource Alliance/ IntermediaWorx inc. It is provided publicly strictly for informational purposes within non-commercial use and not for purposes of resale, distribution, public display or performance. Unless otherwise indicated on this web based page, sharing, re-posting, re-publishing of this work is strictly prohibited without due permission from the publishers. Also, certain content may be licensed from third-parties. The licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages (which his incorporated herein by reference).The publishers/producers of this site and its contents such as videos, graphics, text, and other materials published are not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 9-1-1 immediately. This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.